High-frequency irreversible electroporation synergizes with PD-1/PD-L1 inhibitor BMS-1 and TLR7/8 agonist R848 to potentiate liver cancer antitumor immunity

Figure 6 Safety assessment of high-frequency irreversible electroporation combined with BMS-1 and R848 in hepatoma 22 tumor-bearing mice. A: Dynamic body weight changes of mice across all groups post-treatment (n = 8); B: Quantification of mouse body weights in each group at 21 days post-treatment (n = 8); C: Hematoxylin-eosin staining of major organs (heart, liver, spleen, lung, kidney) in mice from each group post-treatment, showing no obvious histopathological damage; D-H: Serum biochemical analysis shows no significant intergroup differences in liver function markers (aspartate aminotransferase, alanine aminotransferase), a cardiac injury marker (creatine kinase MB isoenzyme), and renal function parameters (creatinine, blood urea nitrogen) post-treatment (n = 8). H-FIRE: High-frequency irreversible electroporation; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; CK-MB: Creatine kinase MB isoenzyme; CREA: Creatinine; BUN: Blood urea nitrogen.